PCP Induced Schizophrenia Model
logo

PCP Induced Schizophrenia Model

PCP is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, reproduces a schizophrenia-like psychosis including positive symptoms, negative symptoms and cognitive dysfunction. Thus, the glutamatergic neuronal dysfunction hypothesis is one of the main explanatory hypotheses and PCP-treated animals have been utilized as an animal model of schizophrenia.

Unlocking Key Models for Schizophrenia Research: Comprehensive Analysis of Mechanisms, Workflow, and Validation Data of PCP-Induced Animal Models

This poster will provide you with the following details:

Authoritative Model Analysis

Delves into the neural mechanisms of Phencyclidine (PCP)-induced models, highlighting their unique advantages in simulating positive/negative symptoms and cognitive deficits of schizophrenia. Serves as a reliable platform for disease mechanism research and drug development.

Visualized Step-by-Step Protocol

Clearly demonstrates standardized workflows—from animal modeling and behavioral testing to data analysis—enabling rapid replication of high-consistency models and saving valuable R&D time.

Critical Behavioral Validation Data

Focuses on three core experimental outcomes, providing directly applicable empirical support for protocol design:

  • Open field test: Quantifies spontaneous activity and anxiety-like behavior, revealing hypoactivity linked to negative symptoms.
  • Prepulse inhibition (PPI) test: Precisely detects sensorimotor gating deficits, modeling core features of positive symptoms.
  • Novel object recognition (NOR) test: Objectively assesses working memory and cognitive flexibility impairments.
Enter Your Email to Subscribe

Enter your E-mail and receive the latest news from us

Copyright © Ace Therapeutics. All Rights Reserved.
Top